TBI-302(Therapure Biopharma, Inc.)(TBI-302(Therapure Biopharma, Inc.))

概要

基本信息

药物类型

偶联药物

别名

Haemoglobin-conjugated floxuridine

+ [1]

靶点

TYMS

作用机制

TYMS抑制剂(胸苷酸合成酶抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症-

非在研适应症

结直肠癌肝细胞癌肝癌+ [1]

原研机构

Therapure Biopharma, Inc.

在研机构-

非在研机构

Therapure Innovations

Therapure Biopharma, Inc.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

使用我们的XDC技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

1

项与 TBI-302(Therapure Biopharma, Inc.) 相关的临床试验

NCT03908840 / Unknown status临床1期

An Open-label, Multicenter, Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Non-resectable, Non-transplantable, Non-radiofrequency Ablation (RFA) Treatable Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. TBI 302 is being developed for the treatment of inoperable HCC by intravenous infusion. The objective is to determine the safety and tolerability of TBI 3002.

开始日期2019-12-01

申办/合作机构

Therapure Biopharma, Inc.

100 项与 TBI-302(Therapure Biopharma, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 TBI-302(Therapure Biopharma, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 TBI-302(Therapure Biopharma, Inc.) 相关的专利（医药）

登录后查看更多信息

1

项与 TBI-302(Therapure Biopharma, Inc.) 相关的文献（医药）

1990-08-01·Archives of Surgery

Intra-arterial Floxuridine vs Systemic Fluorouracil for Hepatic Metastases From Colorectal Cancer

Article

作者: Robert J. Fitzgibbons ; Michael J. O'Connell ; Loren K. Tschetter ; J. Kirk Martin ; James E. Krook ; Joseph Rubin ; David M. Nagorney ; James A. Mailliard ; Harry S. Wieand

Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection. Eligible patients were randomized to hepatic arterial chemotherapy with an implanted infusion pump or systemic chemotherapy. No crossover between treatment arms was permitted, and patients were followed up to progression and death. Objective tumor response was observed in 48% of patients receiving intra-arterial floxuridine and in 21% of patients receiving intravenous fluorouracil. Time to hepatic progression was significantly longer in the group given intra-arterial therapy: 15.7 vs 6.0 months. However, time to overall progression (6.0 vs 5.0 months) and survival (12.6 vs 10.5 months) were not statistically different. Based on these data, we cannot recommend treatment with intra-arterial floxuridine as given in this study for metastatic colorectal cancer to the liver.

100 项与 TBI-302(Therapure Biopharma, Inc.) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝癌	临床1期	美国	Therapure Innovations	2020-08-24
肝细胞癌	临床1期	美国	Therapure Biopharma, Inc.	2019-12-01
不能切除性胰腺癌	临床1期	美国	Therapure Biopharma, Inc.	2019-12-01
结直肠癌	临床1期	加拿大	Therapure Innovations	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


AACR2016	临床1期	肝癌二线	-	TBI 302	膚衊襯願網願鬱範糧觸(壓艱糧網範壓鹹範網積) = 襯鹽遞鬱蓋淵選顧蓋糧餘廠鹹淵積醖觸壓憲膚 (鬱糧築餘遞築選壓鹹夢 )	-	2016-07-15
				Saline	膚衊襯願網願鬱範糧觸(壓艱糧網範壓鹹範網積) = 遞鹽鹽醖鑰窪鑰繭醖願餘廠鹹淵積醖觸壓憲膚 (鬱糧築餘遞築選壓鹹夢 )